Core Viewpoint - Flagstar Financial (FLG) is anticipated to report a year-over-year increase in earnings despite lower revenues for the quarter ended September 2025, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus EPS estimate for Flagstar Financial is a loss of $0.06 per share, reflecting a year-over-year change of +91.3%. Revenues are projected to be $514.03 million, down 17.5% from the previous year [3]. - The upcoming earnings report is scheduled for October 24, and the stock may rise if the actual numbers exceed expectations, while a miss could lead to a decline [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 11.81% higher, indicating a collective reassessment by analysts [4]. - The Most Accurate Estimate for Flagstar Financial is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.51%, suggesting a bullish outlook on the company's earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Flagstar Financial currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Flagstar Financial was expected to post a loss of $0.12 per share but actually reported a loss of -$0.14, resulting in a surprise of -16.67% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates twice [14]. Industry Comparison - Valley National (VLY), another player in the Zacks Banks - Northeast industry, is expected to report an EPS of $0.26 for the same quarter, indicating a year-over-year change of +44.4% and revenues of $512.75 million, up 8.5% from the previous year [18]. - Valley National's consensus EPS estimate has been revised 0.5% higher recently, with an Earnings ESP of +2.6% and a Zacks Rank of 2, suggesting a strong likelihood of beating the consensus EPS estimate [19].

The market expects Virtus Investment Partners (VRTS) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expecte ...

Core Insights - Valero Energy Corporation (VLO) is scheduled to report its third-quarter 2025 results on October 23, 2025, before the market opens [1] - In the previous quarter, VLO's adjusted earnings were $2.28 per share, surpassing the Zacks Consensus Estimate of $1.73, mainly due to increased refining margins and lower total costs [1] Earnings Performance - VLO has missed the Zacks Consensus Estimate in one of the last four quarters but has beaten it three times, resulting in an average surprise of approximately 130% [2] - The Zacks Consensus Estimate for third-quarter earnings per share is $2.94, reflecting a 158% increase from the same period last year [2] Revenue Expectations - The Zacks Consensus Estimate for revenues stands at $29.7 billion, indicating a 9.6% decrease compared to the previous year's figure [3] Market Conditions - Average spot prices for West Texas Intermediate (WTI) crude in July, August, and September were $68.39, $64.86, and $63.96 per barrel, respectively, which were lower than the average prices of $81.80, $76.68, and $70.24 per barrel in the same months of the previous year [4] - Lower oil prices are expected to positively impact VLO's bottom line, as crude serves as a raw material for producing final petroleum products [5] Earnings Outlook - The current model does not predict an earnings beat for VLO, as it has an Earnings ESP of -4.85% and a Zacks Rank of 2 (Buy) [6][8]

Core Viewpoint - Teledyne Technologies (TDY) is set to release its third-quarter 2025 results on October 22, with expectations of a year-over-year earnings increase of 7.8% and revenue growth of 5.9% [5][9]. Group 1: Factors Influencing Q3 Results - The acquisition of Maretron in July 2025 is expected to enhance TDY's performance by expanding its product line in high-end marine technology, particularly through the integration of Maretron's digital switching and vessel monitoring systems into the Raymarine business [2]. - Solid organic sales in defense electronics and growth from recent acquisitions are anticipated to positively impact the Aerospace & Defense Electronics unit's revenue [3]. - The Instrumentation segment is likely to benefit from increased sales of marine instrumentation, driven by stronger offshore energy and subsea defense markets [3]. Group 2: Challenges and Cautions - Ongoing global trade uncertainties and potential new tariffs may have influenced customer purchasing decisions, leading to flat revenues in the Digital Imaging segment for Q3 [4]. - Cautious market expectations, especially regarding short-cycle businesses, are expected to limit overall top-line growth [4]. Group 3: Earnings Expectations - The Zacks Consensus Estimate for TDY's earnings is $5.50 per share, reflecting a 7.8% increase year-over-year, while revenue is estimated at $1.53 billion, indicating a 5.9% improvement [5][9]. - The company's Earnings ESP is -0.87%, suggesting that an earnings beat is not anticipated this quarter [6]. Group 4: Comparative Analysis - Other companies in the sector, such as GE Aerospace, Howmet Aerospace, and CurtissWright, are expected to report earnings beats, with respective Earnings ESPs of +2.01%, +0.30%, and +1.45% [10][11][12].

Core Viewpoint - Viking Therapeutics (VKTX) is expected to report a loss of 70 cents per share for Q3 2025, with no revenues anticipated due to the absence of marketed drugs in its portfolio [2][5]. Financial Performance - The company's earnings have consistently missed estimates, with a negative average surprise of 15.65% over the past four quarters, including a 31.82% miss in the last reported quarter [3][4]. - Loss estimates for 2025 have increased from $2.39 to $2.45 per share in the last 60 days, indicating ongoing operational challenges [2][5]. Pipeline Updates - The upcoming investor call is expected to focus on updates regarding three key candidates: VK2735 for obesity, VK2809 for non-alcoholic steatohepatitis (NASH), and VK0214 for X-linked adrenoleukodystrophy (X-ALD) [7]. - VKTX has initiated a late-stage program for VK2735, which includes two phase III studies (VANQUISH-1 and VANQUISH-2) targeting different obesity patient groups [8]. - Investors are looking for updates on the oral version of VK2735, which showed mixed results in a mid-stage study, particularly concerning patient dropout rates due to adverse effects [9]. Competitive Landscape - VKTX is facing intense competition in the obesity treatment market from established players like Eli Lilly and Novo Nordisk, which are advancing their own oral treatments [18][19]. - The company is exploring partnership opportunities to support the clinical development of its NASH and X-ALD programs due to limited resources [19]. Stock Performance and Valuation - Year-to-date, VKTX's stock has declined nearly 14%, underperforming both the industry and the broader market [12]. - The stock is trading at a premium valuation, with a price/book ratio of 4.91 compared to the industry average of 3.41, indicating a higher valuation relative to its peers [15]. Financial Position - VKTX maintains a strong financial position with $808 million in cash and no outstanding debt, providing sufficient liquidity for ongoing operations and research and development [17].

Core Viewpoint - West Pharmaceutical Services (WST) is expected to report third-quarter 2025 results on October 23, with a history of earnings surprises, averaging 16.81% over the last four quarters [1] Q3 Estimates - The company anticipates third-quarter revenues between $785 million and $795 million, reflecting an organic sales growth of 2.5% to 3.5% [2] - Adjusted diluted earnings per share (EPS) are projected to be in the range of $1.65 to $1.70 [2] - The Zacks Consensus Estimate for revenues stands at $788 million, indicating a 5.5% increase year-over-year, while the consensus for earnings is $1.67 per share, showing a decline of 9.7% year-over-year [3] Revenue and Segment Performance - Total revenues are estimated at $786.8 million, representing a 3% organic improvement year-over-year, with adjusted EPS estimated at $1.66 [4] - Proprietary Products segment sales are expected to reach $638 million, reflecting an organic growth of 3.7%, while Contract-Manufactured Products segment sales are projected at $148.8 million [4] - Operating profit for Proprietary Products and Contract-Manufactured Products segments is likely to decline by 5.6% and 24.8%, respectively [4] Growth Drivers - The company is positioned for steady results, driven by the strength of its high-value product (HVP) portfolio, particularly in GLP-1 elastomer components and compliance upgrades in Europe [5] - The HVP delivery devices segment is expected to maintain solid demand, with ongoing evaluations of SmartDose for profitability improvements [6] - Contract manufacturing is anticipated to benefit from scaling production at the Dublin facility, partially offsetting weaknesses from certain product phase-outs [6] Challenges - Challenges include destocking effects in generics, capacity constraints in European facilities, and seasonal plant shutdowns, which may pressure gross margins [7][8] - Tariff-related headwinds of $15–$20 million for the year could also impact performance, depending on global trade developments [8]

Core Insights - FirstEnergy Corporation (FE) is set to release its third-quarter 2025 results on October 22, with a previous earnings surprise of 4% in the last quarter [1] Factors Impacting Q3 Performance - FirstEnergy's subsidiary Potomac Edison commissioned a new substation in Morgan County, WV, enhancing power reliability for nearly 2,000 residents and businesses through smart grid technology [2] - The new Klecknersville Substation, energized in August 2025, provides additional power to over 5,000 residents and businesses in Northampton County, PA, supporting regional development [3] - Significant infrastructure upgrades in Westmoreland County improved reliability for 2,300 customers, minimizing outages and accelerating restoration times [5] - These initiatives are expected to enhance service reliability and positively impact quarterly performance [4] Q3 Expectations - The Zacks Consensus Estimate for earnings is 71 cents per share, reflecting a year-over-year decline of 16.5% [7] - Revenue is estimated at $3.86 billion, indicating a 3.5% year-over-year improvement [7] - Total electric distribution deliveries are expected to be 39,638.43 megawatt-hours, down 0.2% from the previous year [7] Earnings Prediction Model - The current Earnings ESP for FirstEnergy is 0.00%, indicating no conclusive prediction for an earnings beat [8] Operating Expenses - Higher operating expenses may offset the benefits gained from infrastructure improvements during the quarter [6][9] Zacks Rank - FirstEnergy currently holds a Zacks Rank of 3, indicating a hold position [10]

Core Insights - Molina Healthcare, Inc. (MOH) is scheduled to report its third-quarter 2025 results on October 22, 2025, with earnings estimated at $3.97 per share and revenues of $10.9 billion [1][7] Earnings Estimates - The earnings estimate for Q3 2025 indicates a year-over-year decrease of 33.9%, while the revenue estimate suggests a growth of 5.4% year over year [2] - For the full year 2025, the revenue estimate is $44.54 billion, reflecting a 9.6% increase year over year, but the earnings per share estimate is $18.87, indicating a decline of 16.7% year over year [3] Historical Performance - Molina Healthcare has beaten the consensus estimate in two of the last four quarters and missed twice, with an average surprise of negative 2.2% [4] Earnings Prediction Model - The current model does not predict an earnings beat for Molina Healthcare, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) [5] Membership and Premiums - The Zacks Consensus Estimate for premiums indicates a growth of 6.3% year over year in Q3, with Medicare premiums expected to reach $1.5 billion, up 8% year over year [6][8] - Medicaid membership is projected to decrease by 2.8% year over year, while Medicare membership is expected to grow by 6.5% [8] Medical Care Ratio and Costs - The consensus mark for the medical care ratio (MCR) in the Marketplace is pegged at 84.67%, up from 73% a year ago, and the total MCR is expected to be 90.32%, up from 89.20% [8] - Rising costs and lower investment income are expected to impact earnings, with a projected 15.3% decline in investment income and over 6% increase in total operating expenses [9]

Core Insights - Avery Dennison Corporation (AVY) is set to report its third-quarter 2025 results on October 22, 2025, with expected revenues of $2.22 billion, reflecting a 1.5% increase year-over-year, while earnings per share (EPS) is estimated at $2.32, indicating a 0.4% decline from the previous year [1][7]. Financial Performance - The Zacks Consensus Estimate for AVY's third-quarter revenues is $2.22 billion, which is a 1.5% rise from the year-ago figure [1]. - The consensus estimate for AVY's earnings has decreased over the past 60 days, now pegged at $2.32 per share, showing a year-over-year dip of 0.4% [1][7]. - Avery Dennison's earnings have beaten the Zacks Consensus Estimates in three of the last four quarters, with an average surprise of 0.4% [3][4]. Segment Performance - The Materials Group segment is expected to see revenues rise by 1.1% year-over-year to $1.51 billion, driven by growth in the base business and specialty labels, although adjusted operating profit is projected to fall by 1.4% to $219 million [10]. - The Solutions Group segment's revenues are estimated at $695 million, reflecting a 1.4% increase from the prior year, with operating profit expected to decrease by 4.4% to $74 million [11][12]. Market Context - Avery Dennison's stock has declined by 25.4% over the past year, compared to a 34.6% decline in the industry [13].

Core Insights - Packaging Corporation of America (PKG) is scheduled to report its third-quarter 2025 results on October 22, with revenue estimates at $2.26 billion, reflecting a 3.4% year-over-year growth, and earnings per share (EPS) estimated at $2.83, indicating a 6.8% increase from the previous year [1][5]. Financial Performance - The Zacks Consensus Estimate for PKG's third-quarter revenues is $2.26 billion, which shows a growth of 3.4% compared to the same quarter last year [1]. - The consensus estimate for earnings is $2.83 per share, representing a year-over-year growth of 6.8% [1]. - PKG has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 2.9% [3][4]. Segment Analysis - The Packaging segment is expected to report revenues of $2.06 billion, which is a 2.6% increase from the prior year, despite a predicted volume decline of 2.5% [8][9]. - Operating income for the Packaging segment is estimated at $340 million, reflecting a 6.2% growth year-over-year [9]. - The Paper segment is projected to have revenues of $151 million, down 5.4% from the previous year, with an operating income estimate of $38 million, indicating a 1.2% decline [10]. Strategic Developments - The acquisition of Greif, Inc.'s containerboard business, finalized in early September, is expected to positively impact PKG's earnings immediately, contributing to the Packaging segment's performance [7]. Stock Performance - Over the past year, PKG shares have decreased by 2.5%, contrasting with a 34.6% decline in the industry [11].